Furthermore, a research in lung cancer showed that SHOX2 promotes tumorigenesis in lung cancer cells through the down-regulation of p53 and the activation of NF-κB, and leads to drug resistance in lung cancer cells through the aberrant regulation of cell cycle progression and the inhibition of apoptosis (Yang et al., 2015). Here, TP53 is linked to lung carcinoma.